Akoya biosciences to partner with acrivon therapeutics for the clinical development of acrivon's proprietary oncosignature® test into a companion diagnostic

The oncosignature® test developed based on acrivon's ap3 platform is a first-of-its-kind spatial signature assay to identify patients most likely to respond to acr-368, an advanced phase 2 targeted oncology agent for solid cancers
AKYA Ratings Summary
AKYA Quant Ranking